Show simple item record

dc.contributor.authorKing, A
dc.contributor.authorDoepner, A
dc.contributor.authorTurton, D
dc.contributor.authorCiobota, DM
dc.contributor.authorDa Pieve, C
dc.contributor.authorWong Te Fong, A-C
dc.contributor.authorKramer-Marek, G
dc.contributor.authorChung, Y-L
dc.contributor.authorSmith, G
dc.date.accessioned2018-03-20T14:56:48Z
dc.date.issued2018-04-25
dc.identifier.citationOrganic & biomolecular chemistry, 2018, 16 (16), pp. 2986 - 2996
dc.identifier.issn1477-0520
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1603
dc.identifier.eissn1477-0539
dc.identifier.doi10.1039/c8ob00432c
dc.description.abstractTrifluoromethyl groups are widespread in medicinal chemistry, yet there are limited 18F-radiochemistry techniques available for the production of the complementary PET agents. Herein, we report the first radiosynthesis of the anticancer nucleoside analogue trifluridine, using a fully automated, clinically-applicable 18F-trifluoromethylation procedure. [18F]Trifluridine was obtained after two synthetic steps in <2 hours. The isolated radiochemical yield was 3% ± 0.44 (n = 5), with a radiochemical purity >99%, and a molar activity of 0.4 GBq μmol-1 ± 0.05. Biodistribution and PET-imaging data using HCT116 tumour-bearing mice showed a 2.5 %ID g-1 tumour uptake of [18F]trifluridine at 60 minutes post-injection, with bone uptake becoming a prominent feature thereafter. In vivo metabolite analysis of selected tissues revealed the presence of the original radiolabelled nucleoside analogue, together with deglycosylated and phosphorylated [18F]trifluridine as the main metabolites. Our findings suggest a potential role for [18F]trifluridine as a PET radiotracer for elucidation of drug mechanism of action.
dc.formatPrint
dc.format.extent2986 - 2996
dc.languageeng
dc.language.isoeng
dc.publisherROYAL SOC CHEMISTRY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleRadiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure.
dc.typeJournal Article
dcterms.dateAccepted2018-03-16
rioxxterms.versionofrecord10.1039/c8ob00432c
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOrganic & biomolecular chemistry
pubs.issue16
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Radioisotope Physics
pubs.publication-statusPublished
pubs.volume16
pubs.embargo.termsNo embargo
icr.researchteamPET Radiochemistry
icr.researchteamPreclinical Molecular Imaging
icr.researchteamRadioisotope Physics
dc.contributor.icrauthorKing, Alice
dc.contributor.icrauthorDa Pieve, Chiara
dc.contributor.icrauthorKramer-Marek, Gabriela
dc.contributor.icrauthorChung, Yuen-Li
dc.contributor.icrauthorSmith, Graham


Files in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0